Inmune Bio Announces Board and Executive Compensation Changes
Ticker: INMB · Form: 8-K · Filed: Jul 5, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Jul 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
Inmune Bio reshuffled its board and is tweaking exec pay. Watch for details.
AI Summary
On July 5, 2024, Inmune Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the election of new directors and potential adjustments to compensatory arrangements for certain officers, though specific details on dollar amounts or new appointments are not yet provided in this initial report.
Why It Matters
Changes in a company's board of directors and executive compensation can signal shifts in strategy, governance, or financial priorities that may impact future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect company strategy and performance, warranting closer monitoring.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- July 5, 2024 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors and departure of certain officers, but specific names and details of the changes are not provided in this initial 8-K filing.
Are there any new executive appointments mentioned?
The filing mentions the appointment of certain officers as part of the Item Information, but does not specify any new appointments or their roles.
What is the nature of the changes to compensatory arrangements?
The filing states 'Compensatory Arrangements of Certain Officers' as an item, but does not provide specific details or dollar amounts regarding these arrangements.
When was this report filed and what is the earliest event date?
This Form 8-K was filed on July 5, 2024, and the earliest event reported is also dated July 5, 2024.
What is Inmune Bio, Inc.'s principal executive office address?
Inmune Bio, Inc.'s principal executive offices are located at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
Filing Stats: 457 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-07-05 16:00:09
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0208951-8k_inmune.htm (8-K) — 23KB
- 0001213900-24-059530.txt ( ) — 193KB
- inmb-20240705.xsd (EX-101.SCH) — 3KB
- inmb-20240705_lab.xml (EX-101.LAB) — 33KB
- inmb-20240705_pre.xml (EX-101.PRE) — 22KB
- ea0208951-8k_inmune_htm.xml (XML) — 4KB
02. Departure of Directors or Principal
Item 5.02. Departure of Directors or Principal Officers, Election of Directors, Appointment of Principal Officers On July 5, 2024, Edgardo Baracchini informed INmune Bio Inc. (the "Company") of his resignation from the board of directors of the Company (the "Board"), effective immediately. Mr. Baracchini has served on the Board since August 2019. On the date of his resignation, Mr. Baracchini served as chairman of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee. Mr. Baracchini's resignation was not the result of any disagreement relating to the Company's policies, operations or practices. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: July 5, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2